These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19782564)

  • 1. Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.
    Agoston GE; Shah JH; Suwandi L; Hanson AD; Zhan X; LaVallee TM; Pribluda V; Treston AM
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6241-4. PubMed ID: 19782564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.
    Shah JH; Agoston GE; Suwandi L; Hunsucker K; Pribluda V; Zhan XH; Swartz GM; LaVallee TM; Treston AM
    Bioorg Med Chem; 2009 Oct; 17(20):7344-52. PubMed ID: 19762246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.
    Agoston GE; Shah JH; Lavallee TM; Zhan X; Pribluda VS; Treston AM
    Bioorg Med Chem; 2007 Dec; 15(24):7524-37. PubMed ID: 17910916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs.
    Suwandi LS; Agoston GE; Shah JH; Hanson AD; Zhan XH; Lavallee TM; Treston AM
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6459-62. PubMed ID: 19782568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
    Leese MP; Jourdan FL; Gaukroger K; Mahon MF; Newman SP; Foster PA; Stengel C; Regis-Lydi S; Ferrandis E; Di Fiore A; De Simone G; Supuran CT; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2008 Mar; 51(5):1295-308. PubMed ID: 18260615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.
    LaVallee TM; Burke PA; Swartz GM; Hamel E; Agoston GE; Shah J; Suwandi L; Hanson AD; Fogler WE; Sidor CF; Treston AM
    Mol Cancer Ther; 2008 Jun; 7(6):1472-82. PubMed ID: 18566218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR studies of 2-methoxyestradiol and development of its analogs as probes of anti-tumor mechanisms.
    Ho A; Kim YE; Lee H; Cyrus K; Baek SH; Kim KB
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3383-7. PubMed ID: 16650989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs--Part II.
    Rao PN; Cessac JW; Boyd JW; Hanson AD; Shah J
    Steroids; 2008 Feb; 73(2):158-70. PubMed ID: 18155740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta.
    Descôteaux C; Leblanc V; Bélanger G; Parent S; Asselin E; Bérubé G
    Steroids; 2008 Oct; 73(11):1077-89. PubMed ID: 18572212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs. Part III.
    Rao PN; Cessac JW; Boyd JW; Hanson AD; Shah J
    Steroids; 2008 Feb; 73(2):171-83. PubMed ID: 18155739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.
    Edsall AB; Agoston GE; Treston AM; Plum SM; McClanahan RH; Lu TS; Song W; Cushman M
    J Med Chem; 2007 Dec; 50(26):6700-5. PubMed ID: 18052315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
    Han GZ; Liu ZJ; Shimoi K; Zhu BT
    Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
    Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW
    Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
    Zhou Q; Gustafson D; Nallapareddy S; Diab S; Leong S; Lewis K; Gore L; Messersmith WA; Treston AM; Eckhardt SG; Sidor C; Camidge DR
    Invest New Drugs; 2011 Apr; 29(2):340-6. PubMed ID: 20084425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of aromatic substituents on the antiproliferative effects of diphenyl ferrocenyl butene compounds.
    Zekri O; Hillard EA; Top S; Vessières A; Pigeon P; Plamont MA; Huché M; Boutamine S; McGlinchey MJ; Müller-Bunz H; Jaouen G
    Dalton Trans; 2009 Jun; (22):4318-26. PubMed ID: 19662309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
    Liu ZJ; Zhu BT
    J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.
    Nguyen A; Top S; Pigeon P; Vessières A; Hillard EA; Plamont MA; Huché M; Rigamonti C; Jaouen G
    Chemistry; 2009; 15(3):684-96. PubMed ID: 19053086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
    Leese MP; Hejaz HA; Mahon MF; Newman SP; Purohit A; Reed MJ; Potter BV
    J Med Chem; 2005 Aug; 48(16):5243-56. PubMed ID: 16078843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 2-methoxyestradiol analogues with antitumor activity.
    Tinley TL; Leal RM; Randall-Hlubek DA; Cessac JW; Wilkens LR; Rao PN; Mooberry SL
    Cancer Res; 2003 Apr; 63(7):1538-49. PubMed ID: 12670902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.